 |
| GlaxoSmithKline CEO Andrew Witty |
Last week, GlaxoSmithKline ($GSK) CEO Andrew Witty told reporters something investors have long been hoping to hear: The company's respiratory newcomers are picking up steam. And that's not just some crystal-ball prediction for the future, he stressed. He's seeing it now. The question is whether Glaxo can keep the momentum going enough to fill the widening holes Advair generics and payer exclusions are shooting into the company's top line. And that's a question even Witty can't answer. "What I am not guaranteeing is exactly how that is going to play out for the rest of the year," he said last week of the market-share grab. More from FiercePharmaMarketing